Klaus Mendla
Consulente / Consigliere presso Angelini Ventures SpA
Profilo
Klaus Mendla acts as an external business development consultant to Angelini Ventures.
He is a life sciences professional with strong scientific background and proven track record in Pharma business development in the field of Central Nervous System (CNS) diseases.
Prior to joining Angelini, Klaus was Global Head of Business Development & Licensing CNS at Boehringer Ingelheim (BI), with worldwide responsibility for all Pharma partnering activities in the company’s therapeutic area CNS diseases.
In this role, Klaus took the lead on developing and implementing BI’s strategy for partnering in the neurology and neuropsychiatry space.
He and his team successfully concluded numerous research collaboration and licensing agreements with Pharma and Biotech companies, with a total deal value in the multi-billion-Euro range.
Before joining BI’s global business development and licensing organization, Klaus was director of Molecular Biology and Neurodegenerative Diseases Research at BI, where he led drug discovery teams focused on novel treatments for Alzheimer’s disease and other neurodegenerative disorders.
Klaus received his PhD degree in Biochemistry and Pharmacology from the University of Muenster (Germany) and completed a postdoctoral fellowship at the University of Heidelberg on the pathophysiology of lysosomal storage diseases.
Posizioni attive di Klaus Mendla
Società | Posizione | Inizio |
---|---|---|
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Consulente / Consigliere | - |
Precedenti posizioni note di Klaus Mendla
Società | Posizione | Fine |
---|---|---|
Boehringer Ingelheim Italia SpA
Boehringer Ingelheim Italia SpA Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Italia SpA engages in the research and development of pharmaceutical drugs for cardiovascular, respiratory and virological diseases. It operates through the following business divisions: prescription and hospital drugs; products for self-medication and well-being; and veterinary medicine. The company was founded in 1972 and is headquartered in Milan, Italy. | Corporate Officer/Principal | - |
Formazione di Klaus Mendla
University of Münster | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Angelini Ventures SpA
Angelini Ventures SpA Investment ManagersFinance Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy. | Finance |
Boehringer Ingelheim Italia SpA
Boehringer Ingelheim Italia SpA Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Italia SpA engages in the research and development of pharmaceutical drugs for cardiovascular, respiratory and virological diseases. It operates through the following business divisions: prescription and hospital drugs; products for self-medication and well-being; and veterinary medicine. The company was founded in 1972 and is headquartered in Milan, Italy. | Health Technology |
- Borsa valori
- Insiders
- Klaus Mendla